Viracta Therapeutics Announces Orphan Drug Designation Granted By FDA For Its All-Oral Combination Of Nanatinostat And Valganciclovir For The Treatment Of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma

by | Nov 29, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.